Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- Home

blood-pressure

10 findings across 8 drug records. Domain pages are descriptive indexes, not advice.

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Most represented records

CagriSema (2)

Survodutide (2)

Mazdutide (1)

Orforglipron (1)

Pemvidutide (1)

Retatrutide (1)

Semaglutide (1)

Tirzepatide (1)

Evidence spread

High evidence 1 Moderate evidence 5 Low evidence 3 Very low evidence 1

CagriSema INVESTIGATIONAL
blood-pressure Decrease
Low evidence

CagriSema reduced SBP versus placebo and versus semaglutide alone in REDEFINE 1.

REDEFINE 1 BP analysis, Hypertension, 2025/2026 Source
PopulationAdults without diabetes, BMI >=30 or >=27 + complication; REDEFINE 1 phase 3a; 68 weeks.
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Comparatorssemaglutide 2.4 mg; cagrilintide 2.4 mg; placebo
Orforglipron MARKETED
blood-pressure Decrease
Moderate evidence

Orforglipron produced significant placebo-adjusted BP decreases in phase 2 T2D and obesity; plateau at >=12 mg.

Wharton S et al., Cardiovasc Diabetol, 2025;24(1):240 Source
PopulationPhase 2 pooled: T2D N=361 (26 wk) and obesity N=234 (36 wk); orforglipron 3-45 mg vs placebo (+dulaglutide in T2D).
Fundingindustry - Eli Lilly and Company
Comparatorsplacebo; dulaglutide 1.5 mg (T2D study)
Retatrutide INVESTIGATIONAL
blood-pressure Decrease
Moderate evidence

Retatrutide lowered SBP/DBP dose-dependently (exploratory) in phase 2 obesity.

Jastreboff AM et al. (retatrutide phase 2), NEJM, 2023;389:514-526 Source
PopulationN=338 adults with obesity; retatrutide 1-12 mg vs placebo; 48 weeks; phase 2 (NCT04881760).
Fundingindustry-Eli Lilly
Comparatorsplacebo
Semaglutide MARKETED
blood-pressure Decrease
Low evidence

Once-weekly semaglutide 2.4 mg reduced office SBP/DBP versus placebo across the STEP 1-5 programme.

Amaro A et al. (STEP cardiometabolic review), Postgrad Med, 2022;134(sup1):18-27 Source
PopulationAdults with overweight/obesity, STEP 1-5; most 68 weeks; RCT.
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Comparatorsplacebo
Survodutide INVESTIGATIONAL
blood-pressure Decrease
Low evidence

Survodutide reduced blood pressure (with waist circumference and triglycerides) in phase 2 obesity cardiometabolic analysis.

Survodutide phase 2 cardiometabolic, Eur Heart J, 2024;45(Suppl 1):ehae666.2895 Source
PopulationN=387 adults BMI >=27 without diabetes; survodutide 0.6-4.8 mg vs placebo; 46 weeks; phase 2.
Fundingindustry - Boehringer Ingelheim / Zealand (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Tirzepatide MARKETED
blood-pressure Decrease
High evidence

Tirzepatide reduced 24-hour ambulatory systolic BP versus placebo (SURMOUNT-1 ABPM substudy); effect partly weight-mediated.

de Lemos JA et al. (SURMOUNT-1 ABPM), Hypertension, 2024;81(4):e41-e43 Source
PopulationN=600 adults BMI >=27, BP <140/90 on stable antihypertensives, SURMOUNT-1 substudy; 36 weeks; RCT.
Fundingindustry - Eli Lilly
Comparatorsplacebo
CagriSema INVESTIGATIONAL
blood-pressure Decrease
Moderate evidence

Clinically relevant BP reductions including in resistant hypertension (REDEFINE 1 post hoc)

Verma S et al. Hypertension 2025;83:e26055 Source
PopulationObese/overweight no diabetes (n=3417), phase 3a post hoc, 68 wk
Fundingindustry-Novo Nordisk
Comparatorsplacebo; semaglutide 2.4 mg; cagrilintide 2.4 mg
Mazdutide MARKETED
blood-pressure Decrease
Moderate evidence

Mazdutide reduced systolic blood pressure vs placebo (GLORY-1)

Mazdutide in Chinese adults with obesity (GLORY-1), NEJM 2025 Source
PopulationChinese overweight/obese (n=610), phase 3 GLORY-1, 48 wk
FundingInnovent Biologics
Comparatorsplacebo
Pemvidutide INVESTIGATIONAL
blood-pressure Decrease
Very low evidence

Improvements in blood pressure without meaningful heart-rate increase or cardiac/arrhythmia imbalance

Altimmune MOMENTUM topline / ADA 2024 Source
PopulationMOMENTUM obesity phase 2 (n=391), 48 wk
Fundingindustry - Altimmune (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Survodutide INVESTIGATIONAL
blood-pressure Decrease
Moderate evidence

Placebo-corrected reductions in systolic and diastolic BP at 4.8 mg

le Roux CW et al. Diabetes Obes Metab 2025 (post hoc, DOI 10.1111/dom.16052) Source
PopulationAdults with obesity, phase 2 post hoc analysis (n=387), 46 wk
Fundingindustry - Novo Nordisk (trial sponsor)
Comparatorsplacebo